AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Zenas BioPharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01J1MG9F4
26.87▼ 1.36 (-4.82%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
28.23
Day's Range
26.73 – 28.33
52-Week Range
13.50 – 44.60
Volume
329.7K
Avg Volume
668.1K
Share Statistics
Shares Outstanding
Employees
167
Exchange
XNAS
Listed
2024-09-13
Share count as of July 31, 2026

Zenas BioPharma, Inc. Common Stock (ZBIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Zenas BioPharma, Inc. Common Stock (ZBIO)
What is Zenas BioPharma, Inc. Common Stock's Market Cap?
Zenas BioPharma, Inc. Common Stock's Market Cap is $1.8B, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's Enterprise Value?
Zenas BioPharma, Inc. Common Stock's Enterprise Value is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's Price / Sales?
Zenas BioPharma, Inc. Common Stock's Price / Sales is 1751.3×, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's EV / Revenue?
Zenas BioPharma, Inc. Common Stock's EV / Revenue is 1186.8×, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's EV / EBITDA?
Zenas BioPharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's Revenue (TTM)?
Zenas BioPharma, Inc. Common Stock's Revenue (TTM) is $1.0M, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's Net Income (TTM)?
Zenas BioPharma, Inc. Common Stock's Net Income (TTM) is -$484.4M, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's EBITDA?
Zenas BioPharma, Inc. Common Stock's EBITDA is -$475.5M, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's Diluted EPS (TTM)?
Zenas BioPharma, Inc. Common Stock's Diluted EPS (TTM) is -7.43, based on as-reported figures from SEC (XBRL) filings.
What is Zenas BioPharma, Inc. Common Stock's EBITDA Margin?
Zenas BioPharma, Inc. Common Stock's EBITDA Margin is -47554.2%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ZBIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Revenue:
License and collaboration revenue—
YoY growth——-100.0%—
Total revenue—
Operating expenses:
Research and development—
General and administrative—
Acquired in-process research and development—
Total operating expenses—
% of revenue10865.9%———
Loss from operations—
% of revenue-10765.9%———
Other income (expense), net:
Interest expense on royalty obligation———
Interest expense on senior secured term loan———
Interest expense on convertible senior notes———
Interest income———
Other income (expense), net—
Total other income (expense), net—
Loss before income taxes—
Income tax provision (benefit)—
Net loss
% of revenue-11145.6%———
Net loss per share - basic (in dollars per share)—
Net loss per share - diluted (in dollars per share)—